Bevacizumab-Vikg
- Biologic
- Prescription only
- Identity checked
- Sources last checked 2026-09-04
This page shows what was measured, who it was measured in, and what that does not settle.
RNAWiki holds very little about this substance. The page shows what there is.
What Bevacizumab-Vikg does in the body
LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).
Bevacizumab is a human vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability.
Why people take it. LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
- Where it acts
- Not recorded.
- Kind of result
- No result is published, so no kind of result applies yet
- Supervision
- Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as protein.
FDA substance registry · 2S9ZZM9Q9V · read 2026-08-29
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 99 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Formulation
A formulation is the exact made-up form a substance comes in.
A picture of it, and where the picture fails
It is like the difference between a whole bean and instant coffee.
Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.
What people get wrong. Two products with the same name are assumed to behave the same. They often do not.
The specific composition and physical form of a product, including salt, excipients and release profile.
What is missing or unclearRead from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
- Several advanced cancers, by cutting off the blood supply a tumour builds for itself
Who is missing from the studies
- Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of LYTENAVA in pediatric patients have not been established.”
US prescribing information · 7f9a3014-b3d4-4943-a83a-92a77d8f947c · read 2026-08-30
On older people, the label states: “In the three completed Phase 3 clinical studies, approximately 70% (238/341) of patients treated with LYTENAVA were ≥ 65 years of age and approximately 47 % (160/341) were ≥ 75 years of age.”
US prescribing information · 7f9a3014-b3d4-4943-a83a-92a77d8f947c · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on the anti-VEGF mechanism of action for bevacizumab products [ see Clinical Pharmacology ( 12.1 )], treatment with LYTENAVA may pose a risk to human embryofetal development.”
US prescribing information · 7f9a3014-b3d4-4943-a83a-92a77d8f947c · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There are no data available on the presence of bevacizumab-vikg in human milk, the effects of bevacizumab-vikg on the breastfed infant or the effects of bevacizumab-vikg on milk production/excretion.”
US prescribing information · 7f9a3014-b3d4-4943-a83a-92a77d8f947c · read 2026-08-30
Where the result stopped carrying
- This is a scope explorer, not a diagnosis engine.
- It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to takeRead from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The studied form is not the form on the shelf.
On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
- It was studied for a different goal
- The studies measured something else entirely. Nothing in this record points to this reason.
- There was nothing to correct
- Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
- Something else had to happen too
- In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
- The change is too small to feel
- A real change can still sit below what a person notices. Nothing in this record points to this reason.
- Day-to-day swing hides it
- Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
- Not enough time yet
- The studies ran longer than the person has waited. Nothing in this record points to this reason.
- It was not taken as studied
- Missed days change the result, and studies count them. Nothing in this record points to this reason.
- Something else changed at the same time
- Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
- The product may not be what it says
- Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
- No recorded reason
- RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to takeRead from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No form or route is recorded.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3.
No source is stored against this line.
What is in the pack
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing is recorded about product quality.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to takeNothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclearRead from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
The exact form studied is not recorded.
No source is stored against this line.
What is sold
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 7f9a3014-b3d4-4943-a83a-92a77d8f947c · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 7f9a3014-b3d4-4943-a83a-92a77d8f947c · read 2026-08-29
LYTENAVA is intravitreal at 3 DOSAGE FORMS AND STRENGTHS Injection: 1.25 mg (0.05 mL of 25 mg/mL) colorless to light brown, opalescent solution for intravitreal injection in a single-dose vial., recorded as fda label in effect 2026-07-16 in the United States.
US prescribing information · 7f9a3014-b3d4-4943-a83a-92a77d8f947c · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
Names and forms linked to this record
Biosimilar of
Evidence on this page does not automatically apply to this one.
What it would be like to takeRead from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
- Which of the trials of Bevacizumab-Vikg studied people like me?
- What was measured, and for how long?
- Was the result a laboratory value or a health outcome?
- What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclearRead from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
How much did people take in the studies?
The sources RNAWiki checked hold nothing for this field.
Why it matters. A result belongs to an amount. Without the amount the result floats free.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Bevacizumab-Vikg are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in peopleRead from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
- FDA substance identifier (UNII)
- 2S9ZZM9Q9V
- RxNorm concept
- 2749110
Checks this page had to pass
Passed
Identity resolved
no open identity hold
Passed
No unresolved merge across substance families
no quarantine open
Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
Passed
Safety mode resolved
Suppression classes recorded: S3.
Passed
Canonical metadata present
slug and display name present
What is missing or unclearRead from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
1 approved application covers products containing this substance. The earliest was BLA761320, approved 20260724 to OUTLOOK THERAPEUTICS, INC..
Drugs@FDA application register · BLA761320 · read 2026-08-29
Marketing status on the register: prescription.
Drugs@FDA application register · BLA761320 · read 2026-08-29
What is missing or unclearRead from sources, not yet reviewed
What to learn next
Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.
- Were people like me actually studied?
- How close is this evidence to something I would notice?
- What does nobody know about this yet?
- What is a formulation?
This order is fixed in code and does not count clicks or time on the page.
What is not here
10 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
- What was measured, goal by goal — found nothing in the sources checked.
- What happened in people — found nothing in the sources checked.
- How close this is to real life — found nothing in the sources checked.
- The path through the body — found nothing in the sources checked.
- Felt, measured, or meaningful — found nothing in the sources checked.
- How long anything takes — found nothing in the sources checked.
- What it may clash with — found nothing in the sources checked.
- Other ways to the same goal — found nothing in the sources checked.
- Claims that go past the evidence — found nothing in the sources checked.
- What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (6)
On the Bevacizumab-Vikg label: indicated for what?
"LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD). LYTENAVA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) ( 1 ).": indications and usage on Bevacizumab-Vikg's label. DailyMed label · 7f9a3014-b3d4-4943-a83a-92a77d8f947c · 2026-07-16
63 registered trials of Bevacizumab-Vikg — at which phases?
- Registered studies posting no result
- 35 of 63
63 registered studies of Bevacizumab-Vikg: 30 phase2, 26 phase3, 14 phase1, 1 early phase1, 1 na. CLINICALTRIALS_SNAPSHOT · 2026-09-01
1 with a PubMed record
Show the evidence
- phase230
- phase326
- phase114
- early phase11
- na1
- completed20
6 more recorded rows
- active not recruiting18
- recruiting18
- withdrawn3
- not yet recruiting2
- terminated1
- unknown1
recorded 2026-09-01 · last checked 2026-09-04
4 of Bevacizumab-Vikg's trials stopped: accrual/recruitment, sponsor decision unspecified, other?
accrual/recruitment (1), sponsor decision unspecified (1) and other (2): Bevacizumab-Vikg's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Low accrual"; 4 of 63 registered studies
Show the evidence
Trial
- NCT03878524terminated; "Low accrual"
- NCT04466917withdrawn; "Sponsor decision to early terminate the study"
- NCT05238831withdrawn; "Withdrawn due to a change in therapeutic interventions."
- NCT06393751withdrawn; "Other - Protocol moved to Withdrawn"
recorded 2026-09-01 · last checked 2026-09-04
Which running trial of Bevacizumab-Vikg could settle lifespan?
NCT01167712 measures Progression-Free Survival, reading out 2026-07-02.
22 open trials; n 692; "Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer"
Show the evidence
Trial
- NCT01167712"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer"; n 692; "Progression-Free Survival"; 2026-07-02
- NCT03587311"Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"; n 96; "Progression free survival (PFS)"; 2026-10-21
- NCT04181060"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer"; n 300; "Progression-free survival (PFS)"; 2026-12-31
- NCT00569127"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor"; n 427; "Central Review-based Progression-Free Survival"; 2027-01-31
- NCT00433511"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer"; n 4994; "Invasive Disease-free Survival (IDFS) Rate at 5 Years"; 2027-02-20
- NCT00588770"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"; n 403; "Overall Survival (OS)"; 2027-02-20
14 further recorded trials
- NCT01081262"Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer"; n 50; "Overall Survival"; 2027-03-12
- NCT02997228"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study"; n 120; "Progression free survival (PFS)"; 2027-06-01
- NCT02971501"Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases"; n 5; "Progression Free Survival (PFS)"; 2027-07-01
- NCT02974621"Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma"; n 70; "Number of Participants With Progression-Free Survival at 6 Months"; 2027-07-17
- NCT05211323"A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer"; n 4; "Progression free survival (PFS)"; 2027-08-10
- NCT05063552"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers"; n 430; "Progression free survival (PFS) (Phase II)"; 2027-12-15
- NCT00565851"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer"; n 1052; "To Determine if Surgical Secondary Cytoreduction in Addition to Adjuvant Chemotherapy Increases the Duration of Overall Survival in Patients With Recurrent Platinum Sensitive Epithelial Ovarian Cancer, Peritoneal Primary or Fallopian Tube…"; 2028-01-01
- NCT07198074"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer"; n 255; "Progression-free survival (PFS)"; 2028-07-01
- NCT07288034"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial"; n 535; "Progression-free survival (PFS) during first-line treatment (Part I)"; 2028-10-08
- NCT07504588"Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy"; n 87; "Progression-free survival"; 2029-04-12
- NCT06160206"Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma"; n 134; "Overall survival (OS)"; 2030-11-30
- NCT07271355"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial"; n 129; "Overall survival (OS)"; 2031-02-28
- NCT06543576"External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer"; n 35; "Progression free survival (PFS)"; 2032-01-31
- NCT07166406"Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial"; n 226; "Overall survival (OS)"; 2034-03-10
Which 3 trials of Bevacizumab-Vikg posted no result?
- Posted no result
- 3 of 3 completed trials
- Registrations
- NCT03030430, NCT00989651 and NCT02020707
- Completion dates
- oldest 2017-06-28; newest 2024-07-18
Show the evidence
Trial
- NCT030304302017-06-28
- NCT009896512020-04-10
- NCT020207072024-07-18
At the median, Bevacizumab-Vikg's trials enrolled 134 people — anything larger?
- Median enrolment
- 134
- Largest enrolment
- 4994
- Registered trials counted
- 63
Where it is registered
Identifiers, relations and other names
The exact record
- UNII
- 2S9ZZM9Q9V
- CAS number
- 216974-75-3
- RxCUI
- 2749110
Relations
- Biosimilar of Bevacizumab
- Trade name
- Lytenava, ALYMSYS, AVZIVI
- Development code
- 12-IGG1, ABP-215, AVA-1, BAT-1706, BAT1706
- Also called
- AVASTIN, BAT 1706 [WHO-DD], BEVACIZUMAB
Sources (4)
Sources
- CLINICALTRIALS_SNAPSHOT K1:2S9ZZM9Q9V#vikg ·
- drugsfda+ema drugsfda+ema ·
- DailyMed label 7f9a3014-b3d4-4943-a83a-92a77d8f947c ·
- Drugs@FDA K1:2S9ZZM9Q9V#vikg ·
ClinicalTrials.gov — US Government work · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
How these records are assembled · Which registers were checked
Index-quality checks
- identity passed: no open identity hold
- required summary fields resolved: 3 required field(s) not terminal: Best-supported result, Biggest unanswered question, Human evidence
- public claims reviewed: 0 reviewed claim(s); drafts are never rendered
- source coverage passed: 4 source rows
- no critical contamination: no quarantine open
- canonical metadata passed: slug and display name present
- no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.